Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1978 - 1978

Published: March 14, 2025

The last two decades have proffered many remarkable choices in managing type 1 and 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), first of which, exenatide, was approved by FDA 2005. Two other major classes drugs also entered market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins 2006, sodium–glucose cotransporter-2 (SGLT-2) with approval occurring 2013. These revolutionized treatment diabetes. Additionally, on horizon, once-weekly basal insulin analog icodec combination semaglutide expected to be available future. Beyond glycemic control, GLP1RAs exhibited benefits conditions associated diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, well neurodegenerative diseases such Alzheimer’s disease. emerging research suggests potential roles certain types cancer, infertility, associative learning. Major cardiovascular events seem lower patients GLP1RAs. While some evidence is robust, findings remain tenuous. It important that clinicians familiar current order provide optimal evidence-based care patients. In not-too-distant future, there may a case prescribe these for outside

Language: Английский

---

Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity

JAMA Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Importance Bariatric surgery, once the criterion standard in obesity treatment, has a small but concerning association with increased suicidality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), originally developed to treat diabetes, now provide substantial efficacy treatment of obesity. However, concerns risk suicidality these medicines have been raised. Objective To evaluate and self-harm randomized, placebo-controlled trials GLP-1 RAs adults diabetes or Data Sources MEDLINE, Embase, ClinicalTrials.gov, Cochrane databases were systematically searched from inception August 29, 2023. Study Selection Reports randomized clinical (RCTs) lasting 6 more months comparing placebo for published peer-reviewed journals identified. Two independent reviewers screened all search-identified studies inclusion. Records outcomes queried primary papers, ClinicalTrials.gov entries, corresponding authors. Extraction Synthesis researchers abstracted data assessed quality validity using PRISMA guidelines. pooled random-effects models. Main Outcomes Measures Pooled incidence completed attempted suicide, occurrences suicidal ideation, self-harm. Results A total 27 144 RCTs meeting inclusion criteria recorded suicide and/or self-harm-related events included 32 357 individuals receiving 046 treated placebo, over 74 740 68 095 person-years follow-up, respectively. Event was very low RA (0.044 per 100 person-years) (0.040 groups, no statistically significant difference (rate ratio [RR], 0.76; 95% CI, 0.48-1.21; P = .24). Subgroup analyses did not suggest differences based on status used. Five considered at bias due loss than 5% participants follow-up. Otherwise, found be heterogeneous nor high bias. Conclusions Relevance There is unlikely an increase suicide-related adverse among within context RCTs. While findings may further ease about effects, continued monitoring warranted identify particular patients who as extended use expands.

Language: Английский

---

The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review

Psychoneuroendocrinology, Journal Year: 2025, Volume and Issue: unknown, P. 107415 - 107415

Published: March 1, 2025

Language: Английский

---

Unraveling neural underpinnings of eating disorders in the female brain: insights from high-field magnetic resonance imaging

American Journal of Clinical Nutrition, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Hypothesizing glucagon-like peptide 1 (GLP-1), agonists promote hypodopaminergia, resulting in heightened addictive reward-seeking and altered mood: Breaking the bubble and adding salt to a wound

Medical Hypotheses, Journal Year: 2025, Volume and Issue: unknown, P. 111612 - 111612

Published: March 1, 2025

Language: Английский

---

Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 Diabetes: A TriNetX-Based cohort study

Diabetes Research and Clinical Practice, Journal Year: 2025, Volume and Issue: unknown, P. 112167 - 112167

Published: April 1, 2025

Language: Английский

---